This study significantly broadened the range of metabolites impacted by UGT2B17 deficiency and identified several lipid subclasses (sphingolipids, phospholipids, carnitines) and amino acid derivatives that could be grouped into a core signature associated with metabolic diseases, namely hypertension, diabetes and obesity. Here, UGT2B17 is linked to metabolic disease.